Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis

 Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis

Shots:

  • The P-IIIb VARSITY study involves assessing of Entyvio (vedolizumab, IV) vs Humira (adalimumab, SC) in 769 patients (anti-TNFα-naïve patients & anti-TNFα-experienced patients) with moderately to severely active UC for 52wks.
  • The P-IIIb VARSITY results: @52wks. Clinical remission rates (31.3% vs 22.5%), CRR in anti-TNFα-naïve & experienced patients (34.2% & 20.3% vs 24.3% & 16%); CRR @14wks. (26.6% vs 21.2%); Durable clinical remission (18.3% vs 11.9%); % of mucosal healing (39.7% vs 27.7%); improvement in QoL (52.0% vs 42.2%);  ≥16-point improvement in IBDQ; published in NEJM
  • Entyvio (IV) is a gut-selective mAb, designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not (VCAM-1) and has received marketing authorization in 60+ countries including the US and EU

Click here to­ read full press release/ article | Ref: Takeda | Image: Robus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post